EA201992862A1 - Назальные лекарственные формы дигидроэрготамина - Google Patents

Назальные лекарственные формы дигидроэрготамина

Info

Publication number
EA201992862A1
EA201992862A1 EA201992862A EA201992862A EA201992862A1 EA 201992862 A1 EA201992862 A1 EA 201992862A1 EA 201992862 A EA201992862 A EA 201992862A EA 201992862 A EA201992862 A EA 201992862A EA 201992862 A1 EA201992862 A1 EA 201992862A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dihydroergotamine
drug forms
nasal drug
administer
dosage form
Prior art date
Application number
EA201992862A
Other languages
English (en)
Inventor
Адитья Нарасимха Мурти
Пьюш Гупта
Арун Джана
Вишал Валлабадас Рати
Гириш Каранх
Раджив Сингх Рагхуванши
Original Assignee
Др. Редди'С Лабораториз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Редди'С Лабораториз Лтд. filed Critical Др. Редди'С Лабораториз Лтд.
Publication of EA201992862A1 publication Critical patent/EA201992862A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящая заявка имеет отношение к назальной дозированной лекарственной форме дигидроэрготамина для лечения мигрени у людей, где упомянутая дозированная лекарственная форма требует менее чем приблизительно 15 мин для введения и при этом требует менее чем четыре распыления для введения эффективной дозы дигидроэрготамина.
EA201992862A 2017-07-02 2018-07-02 Назальные лекарственные формы дигидроэрготамина EA201992862A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741000065 2017-07-02
PCT/IB2018/000842 WO2019008439A1 (en) 2017-07-02 2018-07-02 NASAL GALENIC FORMS OF DIHYDROERGOTAMINE

Publications (1)

Publication Number Publication Date
EA201992862A1 true EA201992862A1 (ru) 2020-06-05

Family

ID=63449497

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992862A EA201992862A1 (ru) 2017-07-02 2018-07-02 Назальные лекарственные формы дигидроэрготамина

Country Status (14)

Country Link
US (1) US20190000753A1 (ru)
EP (1) EP3648738A1 (ru)
JP (2) JP2020530439A (ru)
KR (1) KR20200021992A (ru)
CN (1) CN110831578A (ru)
AU (1) AU2018295505A1 (ru)
BR (1) BR112019027508A2 (ru)
CA (1) CA3068175A1 (ru)
CO (1) CO2020000939A2 (ru)
EA (1) EA201992862A1 (ru)
RU (1) RU2019143750A (ru)
UA (1) UA126201C2 (ru)
WO (1) WO2019008439A1 (ru)
ZA (1) ZA202000059B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ741171A (en) 2015-09-10 2022-01-28 Impel Neuropharma Inc In-line nasal delivery device
CN111936140A (zh) 2018-01-05 2020-11-13 英倍尔药业股份有限公司 通过精密鼻装置的双氢麦角胺的鼻内递送
US11083712B1 (en) 2018-03-20 2021-08-10 Relevale, Inc. Low concentration delivery of an ergoline derivative for treatment of a headache
US10532049B1 (en) * 2018-08-27 2020-01-14 Pharmaceutical Industries Limited Parenteral unit dosage form of dihydroergotamine
EP3893877A4 (en) 2018-12-11 2022-09-14 Satsuma Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE
US11786512B2 (en) * 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate
EP4004138A4 (en) * 2019-12-23 2023-08-09 Scienture, Inc. DIHYDROERGOTAMINE MESYLATE FORMULATIONS AND PRE-FILLED INJECTORS FOR THE THERAPEUTIC ADMINISTRATION THEREOF
WO2022009248A1 (en) * 2020-07-07 2022-01-13 Jordan University Of Science And Technology A pharmaceutical composition for treating migraine headaches and a cosolvent method of preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
CA2880035A1 (en) * 2012-08-24 2014-02-27 Anjan Chatterjee Composition for the treatment of migraine headaches
AU2013361337A1 (en) * 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
JP2016503796A (ja) * 2012-12-21 2016-02-08 マップ ファーマシューティカルズ インコーポレイテッド フルオロエルゴリン誘導体およびその使用
DK3049059T3 (da) * 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine

Also Published As

Publication number Publication date
WO2019008439A1 (en) 2019-01-10
KR20200021992A (ko) 2020-03-02
RU2019143750A3 (ru) 2021-08-03
BR112019027508A2 (pt) 2020-07-07
ZA202000059B (en) 2021-07-28
AU2018295505A1 (en) 2020-01-23
UA126201C2 (uk) 2022-08-31
JP2020530439A (ja) 2020-10-22
RU2019143750A (ru) 2021-08-03
CN110831578A (zh) 2020-02-21
US20190000753A1 (en) 2019-01-03
CA3068175A1 (en) 2019-01-10
EP3648738A1 (en) 2020-05-13
CO2020000939A2 (es) 2020-02-18
JP2022050627A (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
EA201992862A1 (ru) Назальные лекарственные формы дигидроэрготамина
MX2022013410A (es) Metodos de tratamiento.
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
PH12020551179A1 (en) Methods for treating mitochondrial disorder
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
NZ742382A (en) Sustained-release non-steroidal anti-inflammatory drug delivery
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
EA201501173A1 (ru) Применение адсорбированного гомогената трутневого расплода и витаминов группы d и/или их активных метаболитов для профилактики и лечения острых респираторных заболеваний и гриппа
MX2020005438A (es) Formas de dosificacion de sulfato de morfina disuasivas del abuso.
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca